Bayer HealthCare and Onyx Pharmaceuticals today announced that the final analysis of the Phase III NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous, non-small cell lung cancer (NSCLC) showed that the trial did not meet its primary endpoint of improving overall survival in the first-line setting.

An advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease.

GlaxoSmithKline plc (GSK) has acquired Laboratorios Phoenix S.A.C.yF ('Phoenix'), a leading Argentine pharmaceutical business, for a cash consideration of approximately $253 million.

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation.

Daiichi Sankyo Company Limited ("Daiichi Sankyo") and Ranbaxy Laboratories Limited ("Ranbaxy") announced today that Ranbaxy has launched a generic version of prasugrel in India. The product, called Prasita, is an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Nearly nine in 10 people think feeling weaker is one of the worst parts about aging, according to a recent survey commissioned by Abbott and developed in conjunction with the AGS Foundation for Health in Aging, a nonprofit dedicated to the health and well-being of older adults, which provided expert, independent review.

Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced the signature with Vivalis (NYSE and Euronext: VLS) of a commercial license and collaboration agreement for the discovery and development of fully human monoclonal antibodies against several infectious diseases.